Surgery after induction chemoradiotherapy for non small cell lung cancer: When and why

Journal of B.U.ON.

Volumn 12, Issue 4, 2007, Pages 453-461

  Koletsis, Efstratios N ^a,c   Prokakis, C ^a   Apostolakis, E ^a   Chatzimichalis, A ^b   Dougenis, D ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

Chemotherapy; Induction treatment; Lung cancer; Radiotherapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; MITOMYCIN; NAVELBINE; PACLITAXEL; VINBLASTINE; VINDESINE;

ADULT RESPIRATORY DISTRESS SYNDROME; ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; FISTULA; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; LUNG COMPLICATION; LUNG INJURY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MONOTHERAPY; NEUROTOXICITY; PATIENT SELECTION; POSTOPERATIVE CARE; RADIATION DOSE; REVIEW; SEPSIS; TREATMENT FAILURE; TREATMENT RESPONSE;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE;

EID: 38349096189     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Diagnosis and management of lung cancer: ACCP Evidence-Based Guidelines. Chest 2003; 123: 1S-337S.
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710-1717.
3. Paulson DL, Urschel HC Jr. Selectivity in the surgical treatment of bronchogenic carcinoma. J Thorac Cardiovasc Surg 1971; 62: 554-562.
4. Martini N, Flehinger BJ, Zaman MB et al. Prospective study of 445 lung cancer carcinomas with mediastinal lymph node metastases. J Thorac Cardiovasc Surg 1980; 80: 390-399.
5. Naruke T, Goya T, Tsuchiya R, Suemasu K. The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis. Ann Thorac Surg 1988; 46: 603-611.
6. Pearson FG, DeLarue NC, Ilves R et al. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 1982; 83: 1-11.
7. Dillman RO, Herndon JH, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CAL GB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210-1215.
8. Johnson DH, Turrisi AT, Pass HI. Combined modality treatment for locally advanced non small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT (Eds): Lung Cancer: Principles and Practice (1st edn). New York, Lipincott-Raven, 1996, pp 863-873.
9. Vokes EE. Interactions of chemotherapy and radiation. Semin Oncol 1993; 20: 70-79.
10. Sause W, Kolesar P, Taylor S et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 2000; 117: 358-364.
11. Rosell R, Gomez-Codina J, Camps C et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-158.
12. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-680.
13. Roth JA, Atkinson EN, Fossella F et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21: 1-6.
14. Rosell R, Gomez-Codina J, Camps C et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 47: 7-14.
15. Sugarbaker DJ, Herndon J, Kohman LJ et al. Results of CALGB 8935: a multi-institutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. J Thorac Cardiovasc Surg 1995; 109: 473-485.
16. Albain KS, Rusch VW, Crowley JJ et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13: 1880-1892.
17. Bartelink H, Begg AC, Dewit C et al. Combined treatment with radiation and anticancer drugs: Experimental and clinical results. In: Lehen N (Ed): Radiobiology in Radiotherapy. Berlin, Germany, Springer, 1987, pp 177-199.
18. Martini N, Kris MG, Flehinger BJ et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55: 1365-1373.
19. Liptay MG, Fry WA. Complications from induction regimens for thoracic malignancies. Perioperative considerations. Chest Surg Clin N Am 1999; 9:79-95.
20. Matsubara Y, Takeda S, Mashimo T. Risk stratification for lung cancer surgery- Impact of induction therapy and extended resection. Chest 2005; 128: 3519-3525.
21. Takeda S, Funakoshi Y, Kadota Y et al. Fall in diffusing capacity associated with induction therapy for lung cancer: a predictor of postoperative complications? Ann Thorac Surg 2006; 82: 232-236.
22. Leo F, Solli P, Spaggiari L et al. Respiratory function changes after chemotherapy: an additional risk for postoperative respiratory complications? Ann Thorac Surg 2004; 77: 260-265.
23. Cox JD, Azarnia N, Byhardt RW, Shin KH, Emami B, Pajak TF. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11. J Clin Oncol 1990; 8:1543-1555.
24. Roach M, Gandara DR, Yuo HS et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 1995; 13: 2606-2612.
25. Yamamoto R, Tada H, Kishi A, Tojo T. Effects of preoperative chemotherapy and radiation therapy on human bronchial blood flow. J Thorac Cardiovasc Surg 2000; 119: 939-945.
26. Vester SR, Faber LP, Kittle CF, Warren WH, Jensik RJ. Bronchopleural fistula after stapled closure of bronchus. Ann Thorac Surg 1991; 52: 1253-1257.
27. Fowler WC, Langer CJ, Curran WJ, Keller SM. Postoperative complications after combined neoadjuvant treatment of lung cancer. Ann Thorac Surg 1993; 55: 986-989.
28. Deutch M, Crawford J, Leopold K et al. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non small cell lung cancer. Cancer 1994; 74: 1243-1252.
29. Doddoli C, Thomas P, Thirion X, Serée Y, Giudicelli R, Fuentes P. Postoperative complications in relation with induction therapy for lung cancer. Eur J Cardiothorac Surg 2001; 20: 385-390.
30. Martin J, Ginsberg RJ, Abolhoda A et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001; 72: 1149-1154.
31. Eberhardt W, Wilke H, Stamatis G et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998; 16: 622-634.
32. Adelstein DJ, Rice TW, Rybicki LA et al. Mature results from a phase II trial of accelerated induction chemoradiotherapy and surgery for poor prognosis stage III non-small-cell lung cancer. Am J Clin Oncol 1999; 22: 237-242.
33. Thomas M, Rube C, Semik M et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 1185-1193.
34. Burkes RL, Ginsberg RJ, Shepherd FA et al. Induction chemotherapy with MVP (mitomycin-C+vindesine+cisplatin) for stage III (T1-3,N2,M0) unresectable non-small cell lung cancer: the Toronto experience. Lung Cancer 1993; 9: 377-382.
35. Stamatis G, Eberhard W, Pottgen C. Surgery after multimodality treatment for non-small-cell lung cancer. Lung Cancer 2004; 45: S107-S112.
36. Stamatis G, Djuric D, Eberhardt W et al. Postoperative morbidity and mortality after induction chemoradiotherapy for locally advanced lung cancer: an analysis of 350 operated patients. Eur J Cardiothorac Surg 2002; 22: 292-297.
37. Ginsberg RJ. Surgical considerations after preoperative treatment. Lung Cancer 1994; 10: 213-217.
38. World Health Organization. Handbook for reporting results of cancer treatment. Publication no. 48, WHO, Geneva, 1979.
39. Werner-Wasik M, Xiao Y, Pequignot E et al. Assesment of lung cancer response after non operative therapy: Tumor diameter, bidimensional product and volume - A serial CT scan based study. Int J Radiat Oncol Biol Phys 2001; 51: 56-61.
40. Lever AM, Henderson D, Ellis DA et al. Radiation fibrosis mimicking local recurrence in non small cell carcinoma of the bronchus. Br J Radiol 1984; 57: 178-180.
41. Martini N, Kris MG, Grala R et al. The effects of preoperative chemotherapy on the resectability of non small cell lung carcinoma with mediastinal lymph node metastases (N2,M0). Ann Thorac Surg 1988; 45: 370-379.
42. Faber PL, Kittle CF, Warren WH et al. Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer. Ann Thorac Surg 1989; 47: 669-677.
43. Pottgen C, Levegrun S, Theegarten D et al. Value of 18F-fiuoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and time to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12: 97-106.
44. Schmucking M, Baum RP, Bonnet R, Junker K, Muller KM. Correlation of histologic results with PET findings for tumor regression and survival in locally advanced non-small cell lung cancer after neoadjuvant treatment. Pathologe 2005; 26: 178-189.
45. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol 1998; 9: 1193-1198.
46. Hellwig D, Graeter TP, Ukena D, Georg T, Kirsch CM, Schafers HJ. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. J Thorac Cardiovasc Surg 2004; 128: 892-899.
47. McManus M, Hicks RJ, Matthews J et al. Positron emission tomography is superior to computed tomography scanning for response assessment after radical radiotherapy or chemoradiotherapy in patients with non small cell lung cancer. J Clin Oncol 2003; 21: 1285-1292.
48. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004; 78: 1903-1909.
49. Rusch VW, Albain KS, Crowley JJ et al. Neoadjuvant therapy: a novel and effective treatment for stage IIIb non-small cell lung cancer. Southwest Oncology Group. Ann Thorac Surg 1994; 58: 290-294.
50. Stamatis G, Eberhardt W, Stuben G, Bildat S, Dahler O, Hillejan L. Preoperative chemoradiotherapy and surgery for selected non-small cell lung cancer IIIB subgroups: long-term results. Ann Thorac Surg 1999; 68: 1144-1149.
51. Rusch VW, Albain KS, Crowley JJ et al. Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg 1993; 105: 97-104.
52. Rice TW, Adelstein DJ, Koka A et al. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. Ann Thorac Surg 1995; 60: 586-591.
53. Regnard JF, Icard P, Deneuville M et al. Lung resection after high doses of mediastinal radiotherapy (sixty grays or more). Reinforcement of bronchial healing with thoracic muscle flaps in nine cases. J Thorac Cardiovasc Surg 1994; 107: 607-610.
54. Macchiarini P, Chapelier AR, Monnet I et al. Extended operations after induction therapy for stage IIIb (T4) non-small cell lung cancer. Ann Thorac Surg 1994; 57: 966-973.
55. Daly BD, Fernando HC, Ketchedjian A et al. Pneumonectomy after high-dose radiation and concurrent chemotherapy for non small cell lung cancer. Ann Thorac Surg 2006; 82: 227-231.
56. Taghavi S, Marta GM, Lang G et al. Bronchial stump coverage with a pedicled pericardial flap: an effective method for prevention of postpneumonectomy bronchopleural fistula. Ann Thorac Surg 2005; 79: 284-288.
57. Doddoli C, Barlesi F, Trousse D et al. One hundred consecutive pneumonectomies after induction therapy for non-small cell lung cancer: an uncertain balance between risks and benefits. J Thorac Cardiovasc Surg 2005; 130: 416-425.
58. Lardinois D, Horsch A, Krueger T, Dusmet M, Ris HB. Mediastinal reinforcement after induction therapy and pneumonectomy: comparison of intercostal muscle versus diaphragm flaps. Eur J Cardiothorac Surg 2002; 21: 74-78.
59. Bueno R, Richards WG, Swanson SJ et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000; 70: 1826-1831.
60. Cerfolio RJ, Bryant AS, Spencer SA, Bartolucci AA. Pulmonary resection after high-dose and low-dose chest irradiation. Ann Thorac Surg 2005; 80: 1224-1230.
61. Vora SA, Daly BD, Blaszkowsky L et al. High dose radiation therapy and chemotherapy as induction treatment for stage III non small cell lung carcinoma. Cancer 2000; 89: 1946-1952.
62. Sonett JR, Krasna MJ, Suntharalingam M et al. Safe pulmonary resection after chemotherapy and high-dose thoracic radiation. Ann Thorac Surg 1999; 68: 316-320.
63. Sonett JR, Suntharalingam M, Edelman MJ et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg 2004; 78: 1200-1205.
64. Rendina EA, Venuta F, De Giacomo T, Flaishman I, Fazi P, Ricci C. Safety and efficacy of bronchovascular reconstruction after induction chemotherapy for lung cancer. J Thorac Cardiovasc Surg 1997; 114: 830-835.
65. Ohta M, Sawabata N, Maeda H, Matsuda H. Efficacy and safety of tracheobronchoplasty after induction therapy for locally advanced lung cancer. J Thorac Cardiovasc Surg 2003; 125: 96-100.
66. Klein DS, Wilds PR. The use of PEEP limits the need for increased inspired oxygen tension. Can Anaesth Soc J 1983; 30: 399-405.
67. Yegin A, Erdogan A, Kayacan N, Karsli B. Early postoperative pain management after thoracic surgery; pre- and postoperative versus postoperative epidural analgesia: a randomised study. Eur J Cardiothorac Surg 2003; 24: 420-424.
68. Takamori S, Yoshida S, Hayashi A, Matsuo T, Mitsuoka M, Shirouzu K. Intraoperative intercostal nerve blockade for postthoracotomy pain. Ann Thorac Surg 2002; 74: 338-341.
69. Romana K, Chatzimichalis A, Koletsis E, Zacharia G, Bellenis I, Karamichali E. Ropivacaine and ropivacaine + clonidine for intercostal analgesia after thoracic surgery. Intern Monitor 2002; 14 (Suppl 2): 36.
70. Wheatley GH, Rosenbaum DH, Paul MC et al. Improved pain management outcomes with continuous infusion of a local anesthetic after thoracotomy. J Thorac Cardiovasc Surg 2005; 130: 464-468.
71. Slinger PD. Perioperative fluid management for thoracic surgery: the puzzle of postpneumonectomy pulmonary edema. J Cardiothorac Vasc Anesth 1995; 9: 442-445.
72. Pezzella TA, Adebonojo SA, Hooker SG, Mabogunje OA, Conlan A. Complications of general thoracic surgery. Curr Probl Surg 2000; 37: 733-858.